AbbVie Inc. (ABBV)
196.68
3.81 (1.98%)
At close: Feb 18, 2025, 3:59 PM
196.50
-0.09%
After-hours: Feb 18, 2025, 07:09 PM EST
undefined% (undefined)
| Bid | 196.5 |
| Market Cap | 347.56B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 2.39 |
| PE Ratio (ttm) | 82.29 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 197 |
| Volume | 4,045,406 |
| Avg. Volume (20D) | 6,030,252 |
| Open | 192.00 |
| Previous Close | 192.87 |
| Day's Range | 190.67 - 197.01 |
| 52-Week Range | 153.58 - 207.32 |
| Beta | undefined |
About ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Jan 2, 2013
Employees 55,000
Stock Exchange NYSE
Ticker Symbol ABBV
Website https://www.abbvie.com
Analyst Forecast
According to 19 analyst ratings, the average rating for ABBV stock is "Buy." The 12-month stock price forecast is $211, which is an increase of 7.28% from the latest price.
Buy 84.21%
Hold 15.79%
Sell 0.00%
Next Earnings Release
AbbVie Inc. is scheduled to release its earnings on Apr 25, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+3.39%
AbbVie shares are trading higher after multiple fi...
Unlock content with
Pro Subscription
2 weeks ago
+4.7%
AbbVie shares are trading higher following better-than-expected Q4 financial results.
